Last reviewed · How we verify
lamotrigine (generic Teva)
lamotrigine (generic Teva) is a Anticonvulsant / Mood stabilizer Small molecule drug developed by University of Maryland, Baltimore. It is currently FDA-approved for Epilepsy (adjunctive and monotherapy), Bipolar I disorder maintenance treatment, Lennox-Gastaut syndrome. Also known as: generic lamotrigine.
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.
Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive and monotherapy), Bipolar I disorder maintenance treatment, Lennox-Gastaut syndrome.
At a glance
| Generic name | lamotrigine (generic Teva) |
|---|---|
| Also known as | generic lamotrigine |
| Sponsor | University of Maryland, Baltimore |
| Drug class | Anticonvulsant / Mood stabilizer |
| Target | Voltage-gated sodium channels; glutamate release inhibition |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lamotrigine stabilizes neuronal membranes by blocking sodium channels, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, thereby reducing excessive neuronal activity. These combined effects make it effective as an anticonvulsant and mood stabilizer.
Approved indications
- Epilepsy (adjunctive and monotherapy)
- Bipolar I disorder maintenance treatment
- Lennox-Gastaut syndrome
Common side effects
- Rash (including Stevens-Johnson syndrome risk)
- Dizziness
- Ataxia
- Somnolence
- Headache
- Diplopia
- Nausea
Key clinical trials
- BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lamotrigine (generic Teva) CI brief — competitive landscape report
- lamotrigine (generic Teva) updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI
Frequently asked questions about lamotrigine (generic Teva)
What is lamotrigine (generic Teva)?
How does lamotrigine (generic Teva) work?
What is lamotrigine (generic Teva) used for?
Who makes lamotrigine (generic Teva)?
Is lamotrigine (generic Teva) also known as anything else?
What drug class is lamotrigine (generic Teva) in?
What development phase is lamotrigine (generic Teva) in?
What are the side effects of lamotrigine (generic Teva)?
What does lamotrigine (generic Teva) target?
Related
- Drug class: All Anticonvulsant / Mood stabilizer drugs
- Target: All drugs targeting Voltage-gated sodium channels; glutamate release inhibition
- Manufacturer: University of Maryland, Baltimore — full pipeline
- Therapeutic area: All drugs in Neurology / Psychiatry
- Indication: Drugs for Epilepsy (adjunctive and monotherapy)
- Indication: Drugs for Bipolar I disorder maintenance treatment
- Indication: Drugs for Lennox-Gastaut syndrome
- Also known as: generic lamotrigine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing